# US 8,569,459 B2 · Targeted binding agents directed to sonic hedgehog homolog and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,569,459 B2 - Document ID: US8569459B2 - Status: Granted - Kind: B2 - Application number: 13/478,580 - Filed: 2012-05-23 - Published: 2012-12-27 - Granted: 2013-10-29 - Earliest claimed: 2008-09-19 - Assignees: MedImmune, LLC - Applicants: David Jenkins; Neil Michaud; Naomi Laing; Jaspal Singh Kang - Inventors: David Jenkins; Neil Michaud; Naomi Laing; Jaspal Singh Kang - Web page: https://patentgrep.com/patent/US8569459B2 ## CPC - C07K 16/18: against material from animals or humans - A61P 25/00: Drugs for disorders of the nervous system - A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia - A61P 25/16: Anti-Parkinson drugs - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - A61P 35/00: Antineoplastic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K 2039/505: {comprising antibodies} - C07K 2317/21: from primates, e.g. man - C07K 2317/56: variable (Fv) region, i.e. VH and/or VL - C07K 2317/565: Complementarity determining region [CDR] - C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding - C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics. ## Claims ### Claim 1 An isolated nucleic acid molecule encoding an antibody or binding fragment thereof that specifically binds to sonic Hedgehog Homolog (Shh), wherein the antibody or fragment thereof comprises: (a) a variable heavy (VH) chain complementarity determining region (CDR) 1, CDR2 and CDR3 of SEQ ID NO: 50; and (b) a variable light (VL) chain CDR1, CDR2 and CDR3 of SEQ ID NO: 54. ### Claim 2 (depends on 1) The isolated nucleic acid molecule according to claim 1 wherein the VH sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:46 or SEQ ID NO:50. ### Claim 3 (depends on 1) The isolated nucleic acid molecule according to claim 1 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:48 or SEQ ID NO:52 or SEQ ID NO:54. ### Claim 4 (depends on 2) The isolated nucleic acid molecule according to claim 2 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:48 or SEQ ID NO:52 or SEQ ID NO:54. ### Claim 5 (depends on 2) The isolated nucleic acid molecule according to claim 2 wherein the VH sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:46. ### Claim 6 (depends on 3) The isolated nucleic acid molecule according to claim 3 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:48. ### Claim 7 (depends on 5) The isolated nucleic acid molecule according to claim 5 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:48. ### Claim 8 (depends on 2) The isolated nucleic acid molecule according to claim 2 wherein the VH sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:50. ### Claim 9 (depends on 3) The isolated nucleic acid molecule according to claim 3 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:54. ### Claim 10 (depends on 8) The isolated nucleic acid molecule according to claim 8 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:54. ### Claim 11 (depends on 3) The isolated nucleic acid molecule according to claim 3 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:52. ### Claim 12 (depends on 8) The isolated nucleic acid molecule according to claim 8 wherein the VL sequence of the antibody or fragment thereof comprises the amino acid sequence as shown in SEQ ID NO:52. ### Claim 13 (depends on 5) The isolated nucleic acid molecule according to claim 5 wherein the VH sequence of the antibody or fragment thereof is encoded by SEQ ID NO:45. ### Claim 14 (depends on 6) The isolated nucleic acid molecule according to claim 6 wherein the VL sequence of the antibody or fragment thereof is encoded by SEQ ID NO:47. ### Claim 15 (depends on 13) The isolated nucleic acid molecule according to claim 13 wherein the VL sequence of the antibody or fragment thereof is encoded by SEQ ID NO:47. ### Claim 16 (depends on 8) The isolated nucleic acid molecule according to claim 8 wherein the VH sequence of the antibody or fragment thereof is encoded by SEQ ID NO:49. ### Claim 17 (depends on 9) The isolated nucleic acid molecule according to claim 9 wherein the VL sequence of the antibody or fragment thereof is encoded by SEQ ID NO:53. ### Claim 18 (depends on 16) The isolated nucleic acid molecule according to claim 16 wherein the VL sequence of the antibody or fragment thereof is encoded by SEQ ID NO:53. ### Claim 19 (depends on 11) The isolated nucleic acid molecule according to claim 11 wherein the VL sequence of the antibody or fragment thereof is encoded by SEQ ID NO:51. ### Claim 20 (depends on 16) The isolated nucleic acid molecule according to claim 16 wherein the VL sequence of the antibody or fragment thereof is encoded by SEQ ID NO:51.